本周,诺和诺德及礼来两家GLP-1减重药巨头公司相继发布财报,都重点突出了对下一代减重药的布局,乐观预期推动两家公司股价大涨。当地时间2月6日,礼来公司表示,预计将于今年晚些时候发布其下一代减重药retatrutide的后期试验数据,其中涉及一项针对肥胖和膝关节骨性关节炎患者的68周治疗的研究结果。这比原本预计的2026年2月完成临床的目标提前了数月。目前,礼来已经上市的减重药为替尔泊肽(...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.